A biotechnology company in the United States has administered an experimental anti-ageing gene therapy to a human for the first time, marking a major milestone in the emerging field of cellular rejuvenation. Boston-based Life Biosciences announced that the first participant has received ER-100, an experimental treatment designed to partially reverse
